Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

MLA

Porpaczy, Edit, et al. “Aggressive B-Cell Lymphomas in Patients with Myelofibrosis Receiving JAK1/2 Inhibitor Therapy.” Blood, vol. 132, no. 7, Aug. 2018, pp. 694–706. EBSCOhost, https://doi.org/10.1182/blood-2017-10-810739.

APA

Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., Greiner, G., Gueltekin, S., Heller, G., Herkner, H., Hoermann, G., Kiladjian, J.-J., Kolbe, T., Kornauth, C., Krauth, M.-T., … Sexl, V. (2018). Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 132(7), 694–706. https://doi.org/10.1182/blood-2017-10-810739

Chicago

Porpaczy, Edit, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, et al. 2018. “Aggressive B-Cell Lymphomas in Patients with Myelofibrosis Receiving JAK1/2 Inhibitor Therapy.” Blood 132 (7): 694–706. doi:10.1182/blood-2017-10-810739.